You are here

Amgen's new cancer drug treatment to cost US$178,000

San Francisco

AMGEN Inc's leukaemia drug Blincyto will cost US$178,000 for a standard course of treatment, continuing a trend of high prices for immunotherapy, the newest wave of cancer treatments.

The price includes two US$89,000 cycles of therapy, the median duration of treatment